ROIVANT SCIENCES LTD. Income (Loss) from Continuing Operations, Per Diluted Share
ROIVANT SCIENCES LTD. (ROIV) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$0.54 per share for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2026-05-20
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for the quarter ending 2025-12-31 was -$0.38.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for the quarter ending 2025-09-30 was -$0.17.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for the quarter ending 2025-06-30 was -$0.33, a 3400.00% decline year-over-year.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for the quarter ending 2024-12-31 was -$0.22, a 103.61% decline year-over-year.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for fiscal 2026 was -$0.54.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for fiscal 2025 was -$0.75, a 113.37% decline from fiscal 2024.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for fiscal 2024 was $5.61.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, per diluted share for fiscal 2023 was -$1.10.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | -$0.54 10-K · filed 2026-05-20 | ||||
| 2025-12-31 | -$0.38 10-Q · filed 2026-02-06 | -$0.88 10-Q · filed 2026-02-06 | |||
| 2025-09-30 | -$0.17 10-Q · filed 2025-11-10 | -$0.49 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | -$0.33 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | -$0.75 10-K · filed 2026-05-20 | ||||
| 2024-12-31 | -$0.22 10-Q · filed 2026-02-06 | -$0.46 10-Q · filed 2026-02-06 | |||
| 2024-09-30 | -$0.25 10-Q · filed 2025-11-10 | -$0.25 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $0.01 10-Q · filed 2025-08-11 | ||||
| 2024-03-31 | $5.61 10-K · filed 2026-05-20 | $5.23 10-K · filed 2024-05-30 | |||
| 2023-12-31 | $6.10 10-Q · filed 2025-02-10 | $5.73 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | -$0.28 10-Q · filed 2024-11-12 | -$0.56 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | -$1.10 10-K · filed 2025-05-29 | -$1.58 10-K · filed 2023-06-28 | |||
| 2022-03-31 | -$1.26 10-K · filed 2023-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |